With CAD also suffer from hyperlipidemia and take lipid-lowering drugs (mainly stains in our CAD patients) and do not take n-3 PUFAs or fish oil, which may partly explain these results. Statins are inhibitors of hydroxymethyl glutaryl coenzyme A (HMG-CoA) reductase. These drugs inhibitendogenous HMG-CoA reductase by competition and blocking the mevalonate metabolic pathway in cells, increasing the clearance of serum cholesterol. Therefore, the results do not truly reflect the situation of lipids in CAD patients. Besides, no significant difference was found in n-3/n-6 between controls and CAD patients. Our study had several limitations. First, no SNPs were evaluated in the SCD gene; thus there was no get 115103-85-0 information about the association of the SCD gene polymorphism with the composition of plasma fatty acids. Second, the concentrations of plasma fatty acids are influenced by both dietary intake and metabolic pathways. However, we did not obtain any information about energy intake. Overall, we firstly report that the rs174460 C allele is associated with a higher risk of CAD, and confirm that the rs174537 T allele is associated with a lower risk of CAD. Our results indicate that FADS gene polymorphisms are likely to influence plasma fatty acid concentrations and desaturase activities. Further investigations are needed to explore the potential mechanisms of rs174460 C allele and increased D6D, D9D activities and higher CAD risk.Supporting InformationFigure S1 Representative Chromatograms of plasma fatty acids by gas chromatography. (DOC)FADS Gene, Desaturase Activity and CADFigure S2 High-resolution melting curves of five studiedSNPs. (DOC)Table S1 Amplification primers utilized in the genotype.Wang Chun-Hong (School of Public Health, Wuhan University) and Dr. Xie Yan (School of Basic Medical Sciences, Wuhan University) for their guidance in statistical analysis.(DOC)Author ContributionsConceived and designed the experiments: SWL XZ SML. Performed the experiments: SWL KL PM. Analyzed the data: SWL SYL. Contributed reagents/materials/analysis tools: ZLZ YDZ. Wrote the paper: SWL XZ SML.AcknowledgmentsWe thank all of the participants of the study. Thanks to Wuhan Asia Heart Hospital for assistance with sample collection. We also thank Professor
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) following a high dose conditioning regimen has been the best treatment option for many young patients with hematological disorders. The antitumor activity of this approach is based not only on high dose chemo-radiotherapy given in the conditioning regimen but also on immune-mediated graft-versus-tumor effects [1,2]. These observations are the basis of the development of alloHSCT following nonmyeloablative conditioning, in which eradication of malignant cells depends on graft-versus-tumor effects [3?6]. Pentagastrin biological activity T-cell recovery after allo-HSCT following high-dose conditioning depends on both homeostatic peripheral expansion (HPE) of donor T cells contained in the graft, and T cell neo-production from donor hematopoietic stem cells (thymo-dependent pathway) [7?5]. In young patients given myeloablative allo-HSCT, most circulating T cells during the first months following HSCT are theprogeny of T cells infused with the grafts [16], while neogeneration of T cells by the thymus plays an increasing role in reconstituting the T cell pool beyond day 100 after allo-HSCT [17?2]. Since HPE allow the expansion of both NK cells and non-tolerant T cells, it is general.With CAD also suffer from hyperlipidemia and take lipid-lowering drugs (mainly stains in our CAD patients) and do not take n-3 PUFAs or fish oil, which may partly explain these results. Statins are inhibitors of hydroxymethyl glutaryl coenzyme A (HMG-CoA) reductase. These drugs inhibitendogenous HMG-CoA reductase by competition and blocking the mevalonate metabolic pathway in cells, increasing the clearance of serum cholesterol. Therefore, the results do not truly reflect the situation of lipids in CAD patients. Besides, no significant difference was found in n-3/n-6 between controls and CAD patients. Our study had several limitations. First, no SNPs were evaluated in the SCD gene; thus there was no information about the association of the SCD gene polymorphism with the composition of plasma fatty acids. Second, the concentrations of plasma fatty acids are influenced by both dietary intake and metabolic pathways. However, we did not obtain any information about energy intake. Overall, we firstly report that the rs174460 C allele is associated with a higher risk of CAD, and confirm that the rs174537 T allele is associated with a lower risk of CAD. Our results indicate that FADS gene polymorphisms are likely to influence plasma fatty acid concentrations and desaturase activities. Further investigations are needed to explore the potential mechanisms of rs174460 C allele and increased D6D, D9D activities and higher CAD risk.Supporting InformationFigure S1 Representative Chromatograms of plasma fatty acids by gas chromatography. (DOC)FADS Gene, Desaturase Activity and CADFigure S2 High-resolution melting curves of five studiedSNPs. (DOC)Table S1 Amplification primers utilized in the genotype.Wang Chun-Hong (School of Public Health, Wuhan University) and Dr. Xie Yan (School of Basic Medical Sciences, Wuhan University) for their guidance in statistical analysis.(DOC)Author ContributionsConceived and designed the experiments: SWL XZ SML. Performed the experiments: SWL KL PM. Analyzed the data: SWL SYL. Contributed reagents/materials/analysis tools: ZLZ YDZ. Wrote the paper: SWL XZ SML.AcknowledgmentsWe thank all of the participants of the study. Thanks to Wuhan Asia Heart Hospital for assistance with sample collection. We also thank Professor
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) following a high dose conditioning regimen has been the best treatment option for many young patients with hematological disorders. The antitumor activity of this approach is based not only on high dose chemo-radiotherapy given in the conditioning regimen but also on immune-mediated graft-versus-tumor effects [1,2]. These observations are the basis of the development of alloHSCT following nonmyeloablative conditioning, in which eradication of malignant cells depends on graft-versus-tumor effects [3?6]. T-cell recovery after allo-HSCT following high-dose conditioning depends on both homeostatic peripheral expansion (HPE) of donor T cells contained in the graft, and T cell neo-production from donor hematopoietic stem cells (thymo-dependent pathway) [7?5]. In young patients given myeloablative allo-HSCT, most circulating T cells during the first months following HSCT are theprogeny of T cells infused with the grafts [16], while neogeneration of T cells by the thymus plays an increasing role in reconstituting the T cell pool beyond day 100 after allo-HSCT [17?2]. Since HPE allow the expansion of both NK cells and non-tolerant T cells, it is general.
